Theranostic barcoded nanoparticles for personalized cancer medicine

Zvi Yaari, Dana da Silva, Assaf Zinger, Evgeniya Goldman, Ashima Kajal, Rafi Tshuva, Efrat Barak, Nitsan Dahan, Dov Hershkovitz, Mor Goldfeder, Janna Shainsky Roitman and Avi Schroeder ()
Additional contact information
Zvi Yaari: Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion—Israel Institute of Technology
Dana da Silva: Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion—Israel Institute of Technology
Assaf Zinger: Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion—Israel Institute of Technology
Evgeniya Goldman: Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion—Israel Institute of Technology
Ashima Kajal: Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion—Israel Institute of Technology
Rafi Tshuva: Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion—Israel Institute of Technology
Efrat Barak: Infrastructure Unit, Life Science and Engineering Center, Technion—Israel Institute of Technology
Nitsan Dahan: Infrastructure Unit, Life Science and Engineering Center, Technion—Israel Institute of Technology
Dov Hershkovitz: Clinical Pathology Unit, Rambam Medical Center
Mor Goldfeder: Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion—Israel Institute of Technology
Janna Shainsky Roitman: Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion—Israel Institute of Technology
Avi Schroeder: Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion—Israel Institute of Technology

Nature Communications, 2016, vol. 7, issue 1, 1-10

Abstract: Abstract Personalized medicine promises to revolutionize cancer therapy by matching the most effective treatment to the individual patient. Using a nanoparticle-based system, we predict the therapeutic potency of anticancer medicines in a personalized manner. We carry out the diagnostic stage through a multidrug screen performed inside the tumour, extracting drug activity information with single cell sensitivity. By using 100 nm liposomes, loaded with various cancer drugs and corresponding synthetic DNA barcodes, we find a correlation between the cell viability and the drug it was exposed to, according to the matching barcodes. Based on this screen, we devise a treatment protocol for mice bearing triple-negative breast-cancer tumours, and its results confirm the diagnostic prediction. We show that the use of nanotechnology in cancer care is effective for generating personalized treatment protocols.

Date: 2016
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/ncomms13325 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms13325

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms13325

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().